Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Other Non-Current Assets (2024 - 2025)

Xilio Therapeutics (XLO) has disclosed Other Non-Current Assets for 2 consecutive years, with $1.8 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets rose 1.4% to $1.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.8 million through Dec 2025, up 1.4% year-over-year, with the annual reading at $1.8 million for FY2025, 1.4% up from the prior year.
  • Other Non-Current Assets hit $1.8 million in Q4 2025 for Xilio Therapeutics, roughly flat from $1.8 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $2.8 million in Q1 2024 to a low of $1.8 million in Q2 2024.